Pharma — India Trademark Cases
177 decisions indexed
Page 5 of 6 · 177 total
Ranbaxy Laboratories Limited v.M/S Intas Pharmaceuticals Ltd.
The Delhi High Court addressed a passing off suit filed by Ranbaxy Laboratories against Intas Pharmaceuticals regarding the alleged similarity between their drug trademarks, 'NIFTRAN' and 'NIFTAS'. While the plaintiff sought an interim injunction, the court did not grant a blanket injunction. Instead, it directed the defendant to maintain complete accounts of sales and profits from the product sold under 'NIFTAS', and imposed specific restrictions on packaging types used by the defendant pending further proceedings.
Nne Pharmaplan India Ltd. v.M/S Cgmp Pharmaplan Pvt. Ltd. & Ors.
The Delhi High Court dismissed Nne Pharmaplan India Ltd.'s suit seeking permanent injunction against M/S Cgmp Pharmaplan Pvt. Ltd., which alleged passing off and infringement of its trade name 'PHARMAPLAN'. The court found that despite both companies operating in the pharmaceutical consulting sector, the names were sufficiently distinct ('NNE' vs. 'cGMP') to prevent customer confusion. Furthermore, the plaintiff failed to establish a prima facie case or irreparable loss, especially given their own inaction against other entities using similar terms.
M/S Alkem Laboratories Ltd. v.Mega International (P) Ltd.
The Delhi High Court dismissed M/S Alkem Laboratories Ltd.'s appeal against a judgment that rejected its claim of passing off regarding the trademark 'GEMCAL'. The court found insufficient evidence to establish Alkem as the proprietor or prior user, noting that both parties were concurrent users. Furthermore, the court observed no instances of consumer confusion and noted significant differences in sales figures, concluding that Alkem's claims were unsubstantiated.
Uas Pharmaceuticals Pty.Ltd. v.Ajantha Pharma Limited
The Madras High Court dismissed an appeal filed by Uas Pharmaceuticals, which sought an interim injunction against Ajantha Pharma regarding the use of the trade name 'SUNSTOP'. The court found that despite the appellant's international reputation, they had not established their mark in India. Crucially, the respondent was found to be first in the Indian market with a similar product, leading the court to uphold the denial of the injunction based on the balance of convenience and prima facie evidence.
M/s.Orchid Chemicals & Pharmaceuticals Limited v.M/s.United Biotech Pvt. Ltd.
Orchid Chemicals filed appeals challenging the dismissal of its application for interim injunction against United Biotech, which was marketing a product under the mark 'FORZID' in Tamil Nadu. The court examined claims of trade mark infringement and passing off regarding the pharmaceutical preparation ORZID.
Merck Kgaa v.The Registrar Of Trade Marks
Merck Kgaa appealed an order from the Assistant Registrar of Trade Marks regarding its trade mark 'CANDISTAT'. The core issue revolved around whether the appellant could be granted sufficient time to file necessary evidence in support of its opposition, despite procedural delays. The IPAB set aside the impugned order and allowed the appeal, emphasizing that opportunity must be granted to the applicant.
Amit R. Trivedi Trading As Active Health v.Assistant Registrar Of Trade Marks And ...
The appellant, a pharmaceutical manufacturer, appealed against the Assistant Registrar's refusal to register the trade mark SEREN. The appeal argued that since the product was a prescription drug, there was no likelihood of confusion. However, the IPAB found the marks (SEREN and SERENE) to be patently identical phonetically and structurally, concluding that the likelihood of deception was imminent.
T.T.K.Pharma Limited v.Robapharam Ag
The appeal was filed by T.T.K.Pharma Limited against an order refusing to stay a suit filed by Robapharam Ag regarding the registered Trade Mark "OSSOPAN". The appellant argued that a rectification application under the Trade and Merchandise Marks Act, 1958, had been filed. However, the court dismissed the appeal, finding no merit in the request for a stay.
Apex Laboratories Private Limited v.K.Prasad Reddy
The Madras High Court allowed the petition filed by Apex Laboratories Private Limited seeking rectification and cancellation of a trademark registration granted to K.Prasad Reddy. The court found that the respondent's registration for 'ZINCOVIT' under Class 29 was mischievous and fraudulent, as the petitioner had been a prior user and proprietor of the mark since 1988/1990. Given the clear evidence of malafide intent and copying, the High Court ruled in favor of Apex Laboratories.
M/S Alkem Laboratories Ltd. v.Mega International (P) Ltd.
The Delhi High Court dismissed M/S Alkem Laboratories Ltd.'s appeal against a judgment that rejected its claim of passing off regarding the trademark 'GEMCAL'. The court found insufficient evidence to establish Alkem as the proprietor or prior user, noting that both parties were concurrent users. Furthermore, the court observed no instances of consumer confusion and noted significant differences in sales figures, concluding that Alkem's claims were unsubstantiated.
Kerala Ayurveda Limited v.State Of Kerala
The petitioner sought permission from various state departments, including the Department of Customs/Central Excise, to incorporate a name change in its L2 license. The Commissioner of Excise and the Government rejected these applications, citing violation of the Emblems and Names (Prevention of Improper Use) Act, 1950. The High Court ruled that since the Registrar of Companies had already approved the name change, the subsequent rejection by the Excise authorities was unwarranted.
Allergan Inc. v.Chetana Pharmaceuticals
The plaintiff filed a suit for passing off against the defendant regarding the identical mark "Oxyline" used for medicinal products (eye drop vs. nasal drop). The court examined the claims of senior user status by both parties and the potential confusion arising from using similar marks on vital medicines.
Medley Pharmaceuticals Ltd. v.Khandelwal Laboratories Ltd.
The Bombay High Court dismissed the plaintiff's motion seeking an interim injunction in a passing off suit. The court found that the trade marks, including those with the prefix 'CEF,' are commonly used across the pharmaceutical industry. Given the prevalence of similar prefixes and suffixes derived from chemical compounds like Cefixime, the court held that the plaintiff failed to establish exclusivity or reputation for their mark, thus denying the injunction.
G.D. Searle Llc And Ors. v.Maiden Pharmaceuticals Ltd.
The Delhi High Court addressed applications for ad interim injunction concerning the anti-diarrhea drug LOMOTIL. The court found considerable merit in the plaintiffs' claims that the defendants' products (MICROTIL and MONOTIL) were deceptively similar to LOMOTIL, particularly regarding trade dress, packaging, and color scheme. However, instead of outright banning the defendant's trademarks, the court modified the existing injunctions. The defendants are permitted to market their products under their respective names, provided they significantly alter their product's visual appearance (trade dress) to avoid consumer confusion.
Torrent Pharmaceuticals Limited v.Reddy'S Laboratories Limited
Torrent Pharmaceuticals Limited filed an application for the trade mark 'DOPAMINE'. Reddy'S Laboratories Limited opposed this registration, arguing that 'DOPAMINE' was descriptively similar to their existing mark 'DOPAMET' and was a non-proprietary generic name for a chemical compound. The IPAB ultimately dismissed the appeal, agreeing with the opposition that the mark failed to meet the requirements of Section 9.
Milmet Oftho Industries & Ors. v.Allergan Inc.
The Supreme Court addressed a passing off dispute concerning the pharmaceutical mark 'OCUFLOX' between an Indian company and a multinational corporation. While acknowledging the global nature of medicine and the potential harm from confusion, the court emphasized that the ultimate test remains who was first in the market. The judgment directed the trial court to continue the injunction while expediting the suit for final determination based on evidence regarding prior use.
Pfizer Ireland Pharmaceuticals v.Intas Pharmaceuticals And Anr.
The Delhi High Court granted a temporary injunction in favor of Pfizer Ireland Pharmaceuticals against Intas Pharmaceuticals, finding that the defendants' use of the mark 'LIPICOR' was deceptively and confusingly similar to the plaintiff's globally reputed trademark 'LIPItor'. Despite the plaintiff not yet having entered the Indian market, the court recognized the trans-border reputation of LIPItor. The judgment emphasized the need for a stricter approach in pharmaceutical cases due to the potential disastrous effects on consumer health, thereby protecting the goodwill associated with the original brand.
Usv Limited v.Systopic Laboratories Limited
Usv Limited filed a suit for passing off against Systopic Laboratories Limited, alleging that the latter was deceptively using similar trade marks ('PIO-15'/'PIO-30') for medicinal preparations. The court examined issues of jurisdiction and whether the defendant's use caused confusion or deception.
Sanat Products Ltd. v.Glade Drugs And Nutraceuticals Pvt.
The Delhi High Court granted an interlocutory injunction in a passing off suit concerning pharmaceutical preparations. The plaintiff, Sanat Products Ltd., argued that the defendant's use of the mark 'REFORM' was deceptively and phonetically similar to its established trademark 'REFIRM', leading to potential confusion among consumers and medical practitioners. The court found that the similarity was likely to cause deception, especially given the nature of prescription drugs, and ruled that the balance of convenience favored granting the injunction to prevent irreparable harm to the plaintiff.
Sysmed Laboratories Pvt. Ltd. v.Panbross Pharmaceuticals
The Orissa High Court upheld a temporary injunction granted against Panbross Pharmaceuticals, finding that their product 'HYCAL FORTE' was deceptively similar to Sysmed Laboratories' established drug 'HICAL'. The court emphasized the high risk of consumer confusion in the pharmaceutical sector, where such errors can have disastrous health consequences. Given the phonetic and visual similarity between the marks, the High Court ruled that a prima facie case for passing off existed, thus dismissing the appeal.
Ipca Laboratories Ltd. v.Savita Pharmaceuticals Pvt. Ltd.
The Plaintiff filed a suit seeking to restrain the Defendant from infringing its copyright in cartons/labels and passing off goods under the trade mark 'APPETONE'. The dispute centered on whether the Plaintiff, as a prior user, was entitled to relief despite the Defendant manufacturing similar products. The court dismissed the Notice of Motion.
Raptakos Brett & Co. Ltd. v.Cadila Laboratories Ltd.
Raptakos Brett & Co. Ltd. opposed the trademark application for NEOPLATIN by Cadila Laboratories Ltd., arguing that it was phonetically, visually, and structurally similar to their registered mark NEOPEPTINE. The Tribunal found an apparent conflict between the marks based on overall impression and sustained the opposition.
Khandelwal Laboratories Ltd. v.Fdc Limited
The Delhi High Court vacated an ex-parte injunction restraining the defendant from using the trade mark ZIFI, which was claimed to be deceptively similar to the plaintiff's CEFI. The court found that despite phonetic similarity, the defendant had a family of 'Z' trademarks and strong arguments regarding the weakness of pharmaceutical salt-derived marks. Considering the balance of convenience, the court ruled in favor of the defendant, allowing them to continue using their mark.
Cadila Healthcare Ltd. v.Swiss Pharma Pvt. Ltd. And Anr.
Cadila Healthcare Ltd. filed a suit alleging that Swiss Pharma Pvt. Ltd. was passing off its medicine SUPERDAC as Cadila's product SPARDAC due to deceptive similarity in the names. The trial court dismissed the suit, finding no evidence of deception or confusion. The Gujarat High Court upheld this decision, concluding that the two brand names were not deceptively similar.
Cadila Healthcare Ltd. v.Swiss Pharma Pvt. Ltd.
Cadila Healthcare Ltd. filed a suit alleging that Swiss Pharma Pvt. Ltd. was passing off its medicine, SUPERDAC, as Cadila's product, SPARDAC, due to deceptive similarity in the trade marks. The trial court dismissed the suit, finding no evidence of deception or confusion. The Gujarat High Court upheld this decision, concluding that the two names were not deceptively similar and there was no likelihood of consumer confusion.
Aviat Chemicals Pvt. Ltd. v.Magna Laboratories (Gujarat) Pvt. Ltd.
The plaintiffs filed a civil suit seeking permanent injunction against the defendant for infringing the registered trade mark MVI. The defendant challenged the validity of the registration and alleged that the plaintiff had been using the mark earlier, thus claiming prior user rights. The court ultimately found prima facie evidence of inordinate delay on the part of the plaintiffs.
Cadila Healthcare Limited v.Cadila Pharmaceuticals Limited
The dispute arose from a suit filed by Cadila Healthcare Limited against Cadila Pharmaceuticals Limited regarding the use of trade marks Falcigo and Falcitab for drugs treating cerebral malaria. The appellant claimed that the respondent's mark would cause passing off due to confusing similarity, especially since both were medicines of last resort.
Cadila Healthcare Ltd. v.Union Of India (Uoi) And Ors.
Cadila Healthcare Ltd. challenged an order that rejected its plea to treat opposition proceedings against its 'CONAZOLE' trademark application as abandoned. The respondent (Uoi) argued that the opposing party had filed evidence, and Cadila failed to file its counter-evidence within the stipulated time. The court ultimately upheld the Registrar's decision to grant an extension of time, finding no infirmity in the order.
Wockherdt Ltd. v.Collector Of Central Excise
Wockherdt Ltd. appealed against an order classifying their product, Mannitol Injection B.P. 20% W/V, as a patent or proprietary medicine based on the design of its label. The company argued that simple labeling features like bars and color schemes do not automatically confer proprietary status unless they are registered trademarks or establish exclusive rights. The Tribunal sided with the appellant.
Mahesh Jayalal Dadhia & Another v.M/S. Thio Pharma & Others
The plaintiffs, members of the Dadhia family, sought an injunction restraining the defendants from manufacturing or trading pharmaceutical products bearing specific trademarks (BROSMIN, ACTIZYME, etc.). The dispute centered on ownership rights following a family arrangement and subsequent agreements regarding the joint business. The court found no merit in the Notice of Motion seeking injunction.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.